LeMaitre Vascular

Valuation Analysis

About the Company

LeMaitre Vascular en bref

LeMaitre Vascular (LMAT) is currently trading at 81,99 € with a market capitalization of 1,9 Md €. The trailing P/E ratio stands at 34.54x, with a forward P/E of 28.86x. The 52-week range spans from 68,95 € to 102,98 €; the current price is 20.4% below the yearly high. Year-over-year revenue growth stands at +11.2%. The net profit margin stands at 24.35%.

💰 Dividende

LeMaitre Vascular pays an annual dividend of 0,87 € per share, representing a yield of 1.06%. The payout ratio stands at 31.25%.

📊 Avis des analystes

8 analystes évaluent LeMaitre Vascular (LMAT) au consensus : Acheter. L'objectif de cours moyen est de 103,63 €, soit un potentiel de +26.4% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 89,01 € à 117,81 €.

LeMaitre Vascular : la thèse d'investissement en détail

LeMaitre Vascular (LMAT) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 11.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 41.7% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 71.33%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

À surveiller

• The forward P/E of 28.86x is meaningfully below the trailing 34.54x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 26.4% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.54%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy LeMaitre Vascular?

Compare top-rated brokers — low fees, trusted providers, fully regulated.